Evaluation of Natural and Vaccine-Induced Anti-SARS-CoV-2 Immunity: A Comparative Study between Different Groups of Volunteers.

(1) Background: The production of anti-SARS-CoV-2 antibodies should help minimize the severity of COVID-19 disease. Our focus was to investigate and compare different vaccination schedules, monitoring circulating S-RBD Ab (antibodies anti-Spike protein-Receptor Binding Domain) levels after administering two doses in naïve patients. Likewise, vaccine-stimulated immunity in naïve and previously infected patients was compared.

SARS-CoV-2 infection serology validation of different methods: Usefulness of IgA in the early phase of infection.

Background And Aims: A novel coronavirus (SARS-CoV-2) was isolated from the respiratory samples of patients with pneumonia as showed by the sequence analysis of the virus genomes obtained in Wuhan, China. The antibody response to SARS-CoV-2 is not well understood yet, but the availability of sensitive and specific serological assays will be crucial for the early diagnosis of infection, for epidemiological studies and for defining the presence of neutralizing antibodies in response to a possible vaccine.

Materials And Methods: We tested and compared the performances of one chemiluminescent immunoassay (CLIA), two enzyme-linked immunosorbent assay (ELISA) and an electrochemiluminescence immunoassay (ECLIA).